These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36852831)

  • 1. Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease.
    Reshef ER; Marsiglia M; Bouhadjer K; Chiou CA; O'Brien-Coon D; Reinshagen KL; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):433-439. PubMed ID: 36852831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echographic Assessment of Extraocular Muscle Response to Teprotumumab.
    Tran C; Pham CM; Simmons BA; Warner LL; Fuhrmeister LJ; Shriver EM
    Ophthalmic Plast Reconstr Surg; 2022 Jul-Aug 01; 38(4):336-339. PubMed ID: 34652310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
    Jain AP; Gellada N; Ugradar S; Kumar A; Kahaly G; Douglas R
    Br J Ophthalmol; 2022 Feb; 106(2):165-171. PubMed ID: 33172865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teprotumumab and Orbital Decompression for the Management of Proptosis in Patients With Thyroid Eye Disease.
    Hubschman S; Sojitra B; Ghiam S; Sears C; Hwangbo N; Goldberg RA; Rootman DB
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):270-275. PubMed ID: 37972968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: "Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease".
    Ting MAJ; Liu CY; Korn BS; Kikkawa DO
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):396-397. PubMed ID: 37413681
    [No Abstract]   [Full Text] [Related]  

  • 7. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply Re: "Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease".
    Reshef ER; Marsiglia M; Bouhadjer K; Chiou CA; O'Brien-Coon D; Reinshagen KL; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):397. PubMed ID: 37413682
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 10. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
    Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graves' orbitopathy: extraocular muscle/total orbit area ratio is positively related to the Clinical Activity Score.
    Le Moli R; Pluchino A; Muscia V; Regalbuto C; Luciani B; Squatrito S; Vigneri R
    Eur J Ophthalmol; 2012; 22(3):301-8. PubMed ID: 21786273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of asymmetric thyroid eye disease with teprotumumab.
    Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
    Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related difference in extraocular muscles and its relation to clinical manifestations in an ethnically homogenous group of patients with Graves' orbitopathy.
    Su Y; Liu X; Fang S; Huang Y; Li Y; Zhong S; Wang Y; Zhang S; Zhou H; Sun J; Fan X
    Graefes Arch Clin Exp Ophthalmol; 2022 Feb; 260(2):583-589. PubMed ID: 34477926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Modeling of New-Onset Postoperative Diplopia Following Orbital Decompression for Thyroid Eye Disease.
    Nair AA; Ediriwickrema LS; Dolman PJ; Law G; Harrison AR; Mokhtarzadeh A; Stewart K; Men C; Lucarelli MJ; van Landingham S; Wingelaar M; Verma R; Chen A; Selva D; Garrity J; Eckel L; Kazim M; Godfrey K; Baxter SL; Korn BS; Kikkawa DO
    Ophthalmic Plast Reconstr Surg; 2022 Nov-Dec 01; 38(6):551-557. PubMed ID: 35551414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual field and orbital computed tomography correlation in dysthyroid optic neuropathy due to thyroid eye disease.
    Starks VS; Reinshagen KL; Lee NG; Freitag SK
    Orbit; 2020 Apr; 39(2):77-83. PubMed ID: 31057005
    [No Abstract]   [Full Text] [Related]  

  • 16. [The value of DCE-MRI in assessing the course of thyroid associated ophthalmopathy].
    Wu T; Tang DR; Wang F; Xia S; Sun FY
    Zhonghua Yan Ke Za Zhi; 2017 Jun; 53(6):430-435. PubMed ID: 28606264
    [No Abstract]   [Full Text] [Related]  

  • 17. Radiographic analysis of extraocular muscle volumetric changes in thyroid-related orbitopathy following orbital decompression.
    Hu WD; Annunziata CC; Chokthaweesak W; Korn BS; Levi L; Granet DB; Kikkawa DO
    Ophthalmic Plast Reconstr Surg; 2010; 26(1):1-6. PubMed ID: 20090474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between extent of lacrimal gland prolapse and clinical features of thyroid-associated ophthalmopathy: a retrospective observational study.
    Gao Y; Chang Q; Li Y; Zhang H; Hou Z; Zhang Z; Li Z; Li D
    BMC Ophthalmol; 2022 Feb; 22(1):66. PubMed ID: 35144579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Systemic Steroids and Orbital Radiation for Active Graves Orbitopathy on Postdecompression Extraocular Muscle Volume.
    Kim JW; Lee KH; Woo YJ; Kim J; Keum KC; Yoon JS
    Am J Ophthalmol; 2016 Nov; 171():11-17. PubMed ID: 27542927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graves' ophthalmopathy: eye muscle involvement in patients with diplopia.
    Nagy EV; Toth J; Kaldi I; Damjanovich J; Mezosi E; Lenkey A; Toth L; Szabo J; Karanyi Z; Leovey A
    Eur J Endocrinol; 2000 Jun; 142(6):591-7. PubMed ID: 10832104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.